https://www.selleckchem.com/pr....oducts/Nobiletin(Hex
Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women. Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined. To evaluate the effects of early treatment with Denosumab (⩽ 12 months after starting AIs) compared to a delayed treatment in BC women. In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with AIs therapy; they were divided as study gro
Like
Comment
Share
